Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee ('HREC') approval that was required before dosing can begin in the 5th study arm of the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the 'Study') in Australia.
This news complements similar news issued on November 13, 2024, when initial lead clinical site HREC approval was received for the first 4 arms of the Study. The Company is pleased to have received all of the necessary lead clinical site approvals so quickly. Additional HREC approval is still pending for the other clinical sites, which is expected soon.
The Study is progressing with both patient recruitment and dosing. The milestone of First Patient First Dose occurred in December 2024 as planned. As a reminder, the 5 Study arms are as follows:
Arm 1 - DehydraTECH-CBD capsules
Arm 2 - DehydraTECH-semaglutide capsules
Arm 3 - DehydraTECH-semaglutide combined with DehydraTECH-CBD capsules
Arm 4 - Rybelsus® tablets (positive control)
Arm 5 - DehydraTECH-tirzepatide capsules (with the newly received HREC approval)
'The ability to study two GLP-1 drugs - semaglutide and tirzepatide - in a single study that together comprise well over 90% of the global GLP-1 market is truly a remarkable achievement for a company of our size,' said Richard Christopher, CEO of Lexaria Bioscience Corp. 'Lexaria's ability to utilize our patented DehydraTECH delivery technology to potentially enhance performance characteristics of these drugs, along with our very own DehydraTECH-CBD, all the while utilizing oral dosing as opposed to injections, is a unique opportunity.'
Further Study updates will be provided as and when available.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients enter the bloodstream through oral delivery. Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 48 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as 'anticipate,' 'if,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'could,' 'should,' 'will,' and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Phone: 250-765-6424, ext 202
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
7 minutes ago
- Business Insider
Chinese armored vehicles gain ground in Africa as Gabon unveils VN-1 infantry fighting vehicle
Chinese armored vehicles are steadily gaining prominence across African militaries, with Gabon becoming the latest country to showcase Beijing's defense hardware. Chinese armored vehicles are increasingly prominent among African militaries, with Gabon showcasing the VN-1 IFV during its Independence Day parade. The VN-1, produced by Norinco, equipped with a simpler turret compared to variants in other countries, exemplifies China's customization of defense products. China's growing defense partnerships across Africa emphasize its strategic role in shaping the continent's military alignment and security landscape. Gabon also introduced the WMA-301 105mm wheeled assault gun, highlighting the appeal of versatile Chinese military equipment for various terrains. During its Independence Day parade on August 17, the Central African nation unveiled the eight-wheeled VN-1 infantry fighting vehicle (IFV), signaling both a deepening defense partnership with China and the rising appeal of Chinese-made equipment across the continent. According to Defence Blog, the armored vehicles purchased by Gabon differ significantly from the VN-1C variant previously delivered to Thailand, which is equipped with the advanced UW-4B remotely controlled weapon station. In contrast, Gabon's VN-1 features a simpler, single-seat turret fitted with the 30mm Type 02 cannon. The weapon itself is derived from the Soviet-designed 2A72, a lighter version of the 2A42 gun mounted on the BMP-2 infantry fighting vehicle. The VN-1, produced by China North Industries Corporation (Norinco), has already been supplied to countries such as Venezuela and Thailand. Its introduction into Gabon's arsenal reflects a broader trend in which African governments are increasingly turning to Chinese suppliers for cost-effective and versatile military platforms. Alongside the VN-1, Gabon also presented the WMA-301, a 105mm wheeled assault gun that has become one of China's most widely exported armored vehicles in Africa. The WMA-301 is designed for fire support and is valued for its mobility and ease of deployment in regions with limited infrastructure. Chinese military appeal in Africa For many African states, Chinese military vehicles offer a practical balance between affordability and capability, often accompanied by flexible financing and political goodwill. The growing presence of these platforms at military parades and in operational deployments highlights China's expanding defense footprint on the continent, raising questions about how this shift may influence Africa's security landscape and strategic alignments in the years ahead. Beyond Gabon, countries such as Nigeria, Ghana, Cameroon, Equatorial Guinea, Uganda and the Sahel states have all made significant purchases of Chinese armored vehicles, while Algeria and Tanzania have incorporated a range of Chinese-built tanks, artillery, and drones into their arsenals.
Medscape
3 hours ago
- Medscape
Cholesterol Raises Heart Risks in Young Despite Clean Scans
TOPLINE: In symptomatic adults with a coronary artery calcification (CAC) score of zero, elevated levels of low-density lipoprotein (LDL) cholesterol were associated with increased risks for noncalcified plaques and future coronary heart disease events, especially in those younger than 45 years. METHODOLOGY: Atherosclerosis is noncalcified in early stages, so a zero CAC score — especially in younger people — can obscure early disease and delay prevention. Researchers conducted a cohort study in Denmark to investigate whether high levels of LDL cholesterol could predict the presence of noncalcified plaques and the risk for future cardiovascular events. They included 23,777 adults (median age, 54 years; 61% women) who underwent coronary CT angiography between January 2008 and May 2021 due to symptoms suggestive of coronary artery disease; all had a CAC score of zero. Noncalcified plaques were identified on scan images; data on levels of LDL cholesterol were retrieved from a registry. Outcomes were the occurrence of myocardial infarction and coronary heart disease, assessed over a median follow-up duration of 7.1 years. TAKEAWAY: Overall, 11% of participants had detectable noncalcified plaques. A CAC score of zero was most common among adults younger than 45 years. Each 1 mmol/L increase in levels of LDL cholesterol was associated with 21% increased odds of detecting noncalcified plaques (adjusted odds ratio [aOR], 1.21; 95% CI, 1.16-1.27). The association between elevated levels of LDL cholesterol and higher odds of noncalcified plaques persisted across all age groups but was most pronounced in adults younger than 45 years (aOR, 1.39; 95% CI, 1.23-1.56). Each 1 mmol/L increase in levels of LDL cholesterol predicted a 26% higher risk for myocardial infarction and a 28% higher risk for coronary heart disease, with greater risks in adults younger than 45 years. IN PRACTICE: 'If CAC is used to guide treatment decisions — particularly in younger individuals — repeat CAC assessments and follow-up should be considered to help identify those who may transition to more advanced stages of atherosclerosis over time,' the researchers reported. '[The study] findings are valuable for clinical practice, as they suggest that lowering LDL cholesterol in younger individuals with hypercholesterolemia should be considered independent of existing CAC or not to reduce atherosclerosis progression and lower long-term [coronary heart disease] risk,' they added. SOURCE: This study was led by Malene Højgaard Andersen, of Aarhus University in Aarhus, Denmark. It was published online on August 9, 2025, in the European Heart Journal. LIMITATIONS: Certain residual confounding factors may have remained despite adjustments, as this study was observational. The multicenter design may have introduced referral, selection, and reporting biases that may have affected the interpretation of results. DISCLOSURES: This study was supported by the Danish Cardiovascular Academy, which is funded by the Novo Nordisk Foundation and The Danish Heart Foundation. Several authors reported being minor shareholders; receiving lecture fees, research grants, and advisory board fees; and having other financial ties with multiple pharmaceutical and healthcare companies including Novo Nordisk. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
6 hours ago
- Yahoo
Researchers uncover alarming link between commonplace household chemicals and diabetes: 'A risk factor for several chronic diseases'
Researchers uncover alarming link between commonplace household chemicals and diabetes: 'A risk factor for several chronic diseases' Common household exposures could raise your chances of developing diabetes via "forever chemicals," Mount Sinai researchers have found. What's happening? A new investigation examined blood samples from 360 study participants in New York City, half of whom had recently received diabetes diagnoses and half of whom hadn't. The research team measured PFAS contamination levels. PFAS, or "forever chemicals," are man-made compounds found in cookware coatings, furniture treatments, and waterproof gear. The researchers found that each increase into a different range of chemical exposure corresponded with a 31% jump in diabetes risk. According to a summary of the study, these substances can interfere with the production of amino acids and how the body handles medicines, which disrupts blood sugar management. The chemicals persist in our surroundings and in human tissue because they resist breaking down naturally. Why is this discovery important? PFAS contamination is possible through common household items and drinking water. These compounds accumulate in our bodies over decades, potentially triggering changes in metabolism that lead to long-term illnesses. "Mounting research suggests that PFAS are a risk factor for several chronic diseases, such as obesity, liver disease, and diabetes," said Dr. Damaskini Valvi, who contributed to the research. Rising diabetes rates strain healthcare systems and families nationwide. Understanding contamination sources helps doctors develop better prevention strategies, particularly for vulnerable communities that face higher exposure rates. This research connects pollution to public health outcomes, showing how chemical contamination translates to real medical consequences. What's being done about PFAS exposure? Scientists are calling for expanded research combining contamination and genetic data to understand how chemical exposures interact with metabolism across different life stages. This knowledge could lead to targeted interventions for at-risk populations. Do you worry about having toxic forever chemicals in your home? Majorly Sometimes Not really I don't know enough about them Click your choice to see results and speak your mind. You can reduce your exposure by choosing PFAS-free products when shopping for cookware, carpets, and clothing. Look for items labeled as not being water- or stain-resistant. Support legislation limiting PFAS use in consumer goods by contacting your representatives. Several states have already passed restrictions on these chemicals in food packaging and firefighting foam. Consider filtering your drinking water, as many municipal systems contain PFAS contamination. Reverse osmosis and activated carbon filters help remove these compounds. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
